Cargando…

Impact of COVID-19 on quality checks of solid tumor molecular diagnostic testing-A surveillance by EQAS provider in India

BACKGROUND: Molecular tests in solid tumours for targeted therapies call for the need to ensure precision testing. To accomplish this participation in the External Quality Assessment Program (EQAS) is required. This evaluates the consistency of diagnostic testing procedures and offers guidance for i...

Descripción completa

Detalles Bibliográficos
Autores principales: Shetty, Omshree, Shet, Tanuja, Iyer, Ramya, Gogte, Prachi, Gurav, Mamta, Joshi, Pradnya, Karnik, Nupur, Pai, Trupti, Epari, Sridhar, Desai, Sangeeta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498956/
https://www.ncbi.nlm.nih.gov/pubmed/36137153
http://dx.doi.org/10.1371/journal.pone.0274089
_version_ 1784794889400090624
author Shetty, Omshree
Shet, Tanuja
Iyer, Ramya
Gogte, Prachi
Gurav, Mamta
Joshi, Pradnya
Karnik, Nupur
Pai, Trupti
Epari, Sridhar
Desai, Sangeeta
author_facet Shetty, Omshree
Shet, Tanuja
Iyer, Ramya
Gogte, Prachi
Gurav, Mamta
Joshi, Pradnya
Karnik, Nupur
Pai, Trupti
Epari, Sridhar
Desai, Sangeeta
author_sort Shetty, Omshree
collection PubMed
description BACKGROUND: Molecular tests in solid tumours for targeted therapies call for the need to ensure precision testing. To accomplish this participation in the External Quality Assessment Program (EQAS) is required. This evaluates the consistency of diagnostic testing procedures and offers guidance for improving quality. Outbreak of COVID-19 pandemic led to worldwide lockdown and disruption of healthcare services including participation in EQAS.The present study describes the extended scope of EQAS offered byMPQAP (Molecular Pathology Quality Assurance Program), the first proficiency test provider for solid tumor diagnostics in India. The study surveys the preparedness of molecular testing laboratories in routine diagnostics and participation for quality assessment scheme. METHODS: A documented guideline for measures and precautions to be carried by testing laboratories in performing routine diagnostic tests during the lockdown period were charted and distributed to all MPQAP participant centres. A survey was conducted for MPQAP participants to check whether laboratories were involved in COVID-19 testing and to evaluate the impact of lockdown on the operations of diagnostics procedures. From the acquired response of the survey, 2 cycles out of initially proposed 11 cycles were executed with transformed approach using digital tools and image interpretation modules. FINDINGS: Out of 25 solid tumour testing laboratories registered as participants, 15 consented to participate in survey. The summary of survey conveyed the impact of COVID-19onroutine operations of diagnostics tests such as shortcomings in inventory and human resource management. Thirteen participants showed active willingness and consented to participate in EQAS test scheme. INTERPRETATIONS: The survey findings and assessment of EQAS cycles endorsed the quality testing procedures carried by participating laboratories throughout the lockdown. It highlighted the utility of EQAS participation during pandemic along with emphasis on safety measures for continual improvement in quality of diagnostic services.
format Online
Article
Text
id pubmed-9498956
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-94989562022-09-23 Impact of COVID-19 on quality checks of solid tumor molecular diagnostic testing-A surveillance by EQAS provider in India Shetty, Omshree Shet, Tanuja Iyer, Ramya Gogte, Prachi Gurav, Mamta Joshi, Pradnya Karnik, Nupur Pai, Trupti Epari, Sridhar Desai, Sangeeta PLoS One Research Article BACKGROUND: Molecular tests in solid tumours for targeted therapies call for the need to ensure precision testing. To accomplish this participation in the External Quality Assessment Program (EQAS) is required. This evaluates the consistency of diagnostic testing procedures and offers guidance for improving quality. Outbreak of COVID-19 pandemic led to worldwide lockdown and disruption of healthcare services including participation in EQAS.The present study describes the extended scope of EQAS offered byMPQAP (Molecular Pathology Quality Assurance Program), the first proficiency test provider for solid tumor diagnostics in India. The study surveys the preparedness of molecular testing laboratories in routine diagnostics and participation for quality assessment scheme. METHODS: A documented guideline for measures and precautions to be carried by testing laboratories in performing routine diagnostic tests during the lockdown period were charted and distributed to all MPQAP participant centres. A survey was conducted for MPQAP participants to check whether laboratories were involved in COVID-19 testing and to evaluate the impact of lockdown on the operations of diagnostics procedures. From the acquired response of the survey, 2 cycles out of initially proposed 11 cycles were executed with transformed approach using digital tools and image interpretation modules. FINDINGS: Out of 25 solid tumour testing laboratories registered as participants, 15 consented to participate in survey. The summary of survey conveyed the impact of COVID-19onroutine operations of diagnostics tests such as shortcomings in inventory and human resource management. Thirteen participants showed active willingness and consented to participate in EQAS test scheme. INTERPRETATIONS: The survey findings and assessment of EQAS cycles endorsed the quality testing procedures carried by participating laboratories throughout the lockdown. It highlighted the utility of EQAS participation during pandemic along with emphasis on safety measures for continual improvement in quality of diagnostic services. Public Library of Science 2022-09-22 /pmc/articles/PMC9498956/ /pubmed/36137153 http://dx.doi.org/10.1371/journal.pone.0274089 Text en © 2022 Shetty et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Shetty, Omshree
Shet, Tanuja
Iyer, Ramya
Gogte, Prachi
Gurav, Mamta
Joshi, Pradnya
Karnik, Nupur
Pai, Trupti
Epari, Sridhar
Desai, Sangeeta
Impact of COVID-19 on quality checks of solid tumor molecular diagnostic testing-A surveillance by EQAS provider in India
title Impact of COVID-19 on quality checks of solid tumor molecular diagnostic testing-A surveillance by EQAS provider in India
title_full Impact of COVID-19 on quality checks of solid tumor molecular diagnostic testing-A surveillance by EQAS provider in India
title_fullStr Impact of COVID-19 on quality checks of solid tumor molecular diagnostic testing-A surveillance by EQAS provider in India
title_full_unstemmed Impact of COVID-19 on quality checks of solid tumor molecular diagnostic testing-A surveillance by EQAS provider in India
title_short Impact of COVID-19 on quality checks of solid tumor molecular diagnostic testing-A surveillance by EQAS provider in India
title_sort impact of covid-19 on quality checks of solid tumor molecular diagnostic testing-a surveillance by eqas provider in india
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498956/
https://www.ncbi.nlm.nih.gov/pubmed/36137153
http://dx.doi.org/10.1371/journal.pone.0274089
work_keys_str_mv AT shettyomshree impactofcovid19onqualitychecksofsolidtumormoleculardiagnostictestingasurveillancebyeqasproviderinindia
AT shettanuja impactofcovid19onqualitychecksofsolidtumormoleculardiagnostictestingasurveillancebyeqasproviderinindia
AT iyerramya impactofcovid19onqualitychecksofsolidtumormoleculardiagnostictestingasurveillancebyeqasproviderinindia
AT gogteprachi impactofcovid19onqualitychecksofsolidtumormoleculardiagnostictestingasurveillancebyeqasproviderinindia
AT guravmamta impactofcovid19onqualitychecksofsolidtumormoleculardiagnostictestingasurveillancebyeqasproviderinindia
AT joshipradnya impactofcovid19onqualitychecksofsolidtumormoleculardiagnostictestingasurveillancebyeqasproviderinindia
AT karniknupur impactofcovid19onqualitychecksofsolidtumormoleculardiagnostictestingasurveillancebyeqasproviderinindia
AT paitrupti impactofcovid19onqualitychecksofsolidtumormoleculardiagnostictestingasurveillancebyeqasproviderinindia
AT eparisridhar impactofcovid19onqualitychecksofsolidtumormoleculardiagnostictestingasurveillancebyeqasproviderinindia
AT desaisangeeta impactofcovid19onqualitychecksofsolidtumormoleculardiagnostictestingasurveillancebyeqasproviderinindia